Validation period: 12/7/2022, 10:26:13 AM - 12/8/2022, 10:26:13 AM
BMJ Journals logo
Home/Browse by collection/COVID-19 and Cancer Immunotherapy
Email alerts

COVID-19 and Cancer Immunotherapy

Edited by Paolo Antonio Ascierto and Jason D. Goldman COVID-19 has had a profound impact on the world, and the immunotherapy field offers important insights into clinical practice, immune-related pathophysiology, and other areas that have proven useful to the global healthcare community. Authored by leading voices in the immuno-oncology, infectious disease, and virology fields, this JITC series explores basic insights into the immunology of the novel coronavirus, repurposing of immune-based therapies including the effects of immune-oncology agents, and the affected cancer populations. This series also provides a valuable resource to readers, not only as a source for hypothesis-generation for future basic and translational studies, but as initial guidance in clinical decision-making.

Showing results 1 - 10 of 10

Sorted by most recent

JAK inhibitors and COVID-19
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu

22 April 2022

SITC Society Logo
  • Latest content
  • Browse by collection
  • Archive
  • Top cited articles
Website Terms & ConditionsPrivacy & CookiesContact BMJCookie settingsOnline ISSN: 2051-1426Copyright © 2022 BMJ Publishing Group Ltd and Society for Immunotherapy of Cancer. All rights reserved.